

Variable effects of *Wolbachia* on alphavirus infection in *Aedes aegypti*

1.1 Author names

Brittany L. Dodson¹, Sujit Pujhari², Marco Brustolin³, Hillery C. Metz¹, and Jason L. Rasgon^{1,4,5}

1.2 Affiliation

¹Department of Entomology, Pennsylvania State University, University Park, PA, United States

²Current address: Department of Pharmacology Physiology and Neuroscience, School of Medicine, University of South Carolina, United States

³Current address: Unit of Entomology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

⁴Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, United States

⁵The Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, United States

1.3 Corresponding author

jlr54@psu.edu

1.4 Keyword

Wolbachia, *Aedes aegypti*, alphavirus, Sindbis virus, O'nyong-nyong virus, Mayaro virus

2. Abstract

Wolbachia pipientis (= *Wolbachia*) has promise as a tool to suppress virus transmission by *Aedes aegypti* mosquitoes. However, *Wolbachia* can have variable effects on mosquito-borne viruses. This variation remains poorly characterized, yet the multimodal effects of *Wolbachia* on diverse pathogens could have important implications for public health. Here, we examine the effects of somatic infection with two strains of *Wolbachia* (*wAlbB* and *wMel*) on the alphaviruses Sindbis virus (SINV), O'nyong-nyong virus (ONNV), and Mayaro virus (MAYV) in *Ae. aegypti*. We found variable effects of *Wolbachia* including enhancement and suppression of viral infections, with some effects depending on *Wolbachia* strain. Both *wAlbB*- and *wMel*-infected mosquitoes showed enhancement of SINV infection rates one week post-infection, with *wAlbB*-infected mosquitoes also having higher viral titers than controls. Infection rates with ONNV were low across all treatments and no significant effects of *Wolbachia* were observed. The effects of *Wolbachia* on MAYV infections were strikingly strain-specific; *wMel* strongly blocked MAYV infections and suppressed viral titers, while *wAlbB* did not influence MAYV infection. The variable effects of *Wolbachia* on vector competence underscore the importance of further research into how this bacterium impacts the virome of wild mosquitoes including the emergent human pathogens they transmit.

Impact statement

In recent years, wild populations of *Aedes aegypti* mosquitoes have been deliberately infected with *Wolbachia*—a bacterium that helps to curb the spread of some pathogens including dengue virus. But how does *Wolbachia* affect the ability of mosquitoes to become infected with and spread the many different viruses they encounter in nature? Here, we characterize the effects of *Wolbachia* on three alphaviruses that cause illness in humans—Sindbis virus, O'nyong-nyong virus, and Mayaro virus. We find *Wolbachia* has variable

effects on these pathogens, including significant enhancement of Sindbis virus infections. Our research has important implications for the design of vector control strategies, and suggests further research is needed to understand how *Wolbachia* shapes the replication and transmission of diverse viruses.

3. Data Summary

All data in the study are available in the Figures and supplementary material.

4. Introduction

More than half of the world's population is at risk for vector-borne diseases, with an estimated one billion new infections and one million deaths every year [1]. Vector-borne diseases are an increasing threat to human health due to global travel, insecticide resistance, and climate change [2-5], and novel strategies to combat mosquitoes and the pathogens they transmit are urgently needed. One of the most promising new tools is the bacterium *Wolbachia pipientis* (= *Wolbachia*), which can suppress vector populations [6] and prevent replication of viruses in mosquitoes, an effect called pathogen blocking [7-8].

Wolbachia is a genus of intracellular bacteria present in many arthropod species [9-11]. Because it can suppress the transmission of specific mosquito-borne viruses and parasites when transferred to novel mosquito hosts, *Wolbachia* has been the focus of much recent research (e.g., [12-15]). *Wolbachia*-infected mosquitoes have been released into the field in multiple countries to curb the spread of dengue virus (DENV) by *Ae. aegypti* vectors [8, 9, 16-20]. In some cases, *Wolbachia*-infected animals can replace native populations and retain a pathogen-blocking phenotype for multiple years after release [8, 9, 21-25]. However, native population replacement with *Wolbachia*-infected mosquitoes is not always successful [16, 26-30]. Moreover, the effects of *Wolbachia* on pathogens can be variable and may

depend on factors such as the virus–mosquito–*Wolbachia* strain pairing, environmental conditions, population dynamics, and *Wolbachia* density [8, 13, 31-35]. In several mosquito genera, *Wolbachia* may enhance some pathogens by increasing both infection frequency and infection intensity, including *Plasmodium berghei*, *Plasmodium yoelii*, *Plasmodium gallinaceum*, and West Nile virus (WNV) [35-39]. Our previous work with *Culex tarsalis* demonstrated that a single strain of *Wolbachia* can have different effects on different pathogens. Specifically, the *Wolbachia* strain wAlbB enhanced WNV infection frequency but suppressed Rift Valley fever virus titers [39-40]. These findings of enhancement stress the importance of better understanding the multifaceted effects of *Wolbachia* on vectors and pathogens, as *Wolbachia* has the potential to negatively impact mosquito-borne disease control efforts.

To better understand the range of outcomes *Wolbachia* can have on vector competence, we investigated the effects of two *Wolbachia* strains (wAlbB and wMel) on alphavirus infections in *Aedes aegypti*. We focused on *Ae. aegypti*, one of the most pernicious vectors of medically relevant pathogens, and to date, the only species used for *Wolbachia* field releases. *Wolbachia* is not naturally found in wild populations of *Aedes aegypti* [41-42]. Because previous studies have focused primarily on flaviviruses while neglecting alphaviruses, we studied the alphaviruses Sindbis virus (SINV), O'nyong-nyong virus (ONNV), and Mayaro virus (MAYV). All three viruses are human pathogens and share important characteristics with Chikungunya virus [43-45], an emergent human pathogen spread primarily by *Ae. aegypti* [46]. Infections with these viruses rarely cause mortality, but they do cause significant morbidity (including fever, rash, and arthralgia) and place a significant burden on public health in affected areas [47-49].

SINV has been isolated from wildlife in Eurasia, Africa, and Oceania [50-51], and there have been periodic cases and epidemics in several areas including Finland, Sweden, Russia,

China, Australia, and South Africa [52-57]. Multiple mosquito genera can transmit SINV but *Culex* and *Culiseta* are considered the primary vectors [47, 51, 58-59]. ONNV is endemic in Africa, where there have been epidemics involving millions of people and where anti-ONNV antibodies are detected at high rates in local human populations [60-64]. ONNV is thought to be transmitted mainly by *Anopheles*, but other mosquito species are also susceptible to infection [65-66]. MAYV is endemic in South and Central America and has caused several small-scale outbreaks of febrile illness with prolonged, disabling arthralgia since it was first identified in 1954 [48]. The virus is common in populations of wild primates and is thought to be spread to humans primarily by *Haemagogus janthinomys* [67], though many mosquito species including *Ae. aegypti* can also become infected and transmit MAYV [49, 68-70]. In sum, these alphaviruses are a burden on global human health yet remain poorly understood, including if and how they are affected by *Wolbachia*.

We assessed the ability of *wAlbB* and *wMel* strains of *Wolbachia* to affect infection, dissemination, and transmission of SINV, ONNV, and MAYV in *Ae. aegypti*. We found striking variation in the effects of *Wolbachia* on these viruses, highlighting the need for more research into this bacterium and how it may influence the full diversity of medically relevant arboviruses found in nature.

5. Methods

Mosquitoes, *Wolbachia*, and intrathoracic injections

We used two *Ae. aegypti* colonies. The Rockefeller strain was kindly provided by Dr. George Dimopoulos, Johns Hopkins University, while the Liverpool strain was obtained from BEI resources. Rockefeller mosquitoes were used to test ONNV and SINV, while Liverpool animals were used to test MAYV. All mosquitoes were reared and maintained using standard methods at 27°C ± 1°C, 12:12 hr light:dark cycle at 80% relative humidity in 30 × 30 × 30 cm cages (MegaView Science). Larvae were fed Tropical Flakes (Tetramin, Product

No. 77101) and adults were provided *ad libitum* access to 10% sucrose. Mosquitoes were fed commercially available expired anonymous human blood (Biological Specialty Corporation) for both virus feeds and colony maintenance.

The *Wolbachia* strains *wAlbB* and *wMel* (derived from *Ae. albopictus* and *D. melanogaster*, respectively) were purified from infected *Anopheles gambiae* Sua5B cells and resuspended in Schneider's Insect Media (Sigma Aldrich) using published protocols [71]. A cell lysate negative control was prepared by putting *Wolbachia*-negative Sua5B cells through the *Wolbachia* purification process. *Wolbachia* viability and density from cell cultures were assessed by using the LIVE DEAD BacLight Bacterial Viability Kit (Invitrogen) and a hemocytometer.

Two- to five-day-old adult female *Ae. aegypti* were anesthetized with ice and injected in the thorax as previously described [39] with approximately 0.1 μ l of *Wolbachia* (10^{10} bacteria/mL) or cell lysate control. Mosquitoes were given access to 10% sucrose *ad libitum* and maintained for up to 22 days post-injection (i.e., up to 27 days of age). *Wolbachia* infection rates in somatically-infected mosquitoes were ~100% and *Wolbachia* titers did not vary across injection groups (ANOVA, $F = 1.005$, $P = 0.39$ [Figure S1]).

Generation of virus stocks

SINV (p5'dsMRE16ic) and ONNV (p5'dsONNic/foy) plasmids were kindly provided by Dr. Brian Foy (Colorado State University, Ft. Collins, CO) on filter paper [72-73]. We obtained the MAYV strain BeAr505411 from BEI Resources. For SINV and ONNV, infectious virus stocks were propagated from the plasmid DNA. Specifically, a piece of the filter paper was cut and eluted in 0.1 ml TE buffer for approximately 1 hr. Competent *E. coli* cells (New England Biolabs, #C2987H) were transformed with the eluted plasmid DNA according to the manufacturer's instructions and grown on LB broth selection plates. Colonies were then

picked from plates and grown in LB broth overnight at 37°C in a shaking incubator. Plasmid DNA was isolated from the bacterial culture using the EZNA Plasmid Mini Kit (Omega, Cat # D6942-02) according to the manufacturer's instructions. Plasmids were linearized with the *Ascl* enzyme (New England Biolabs, #R0558S) for SINV and *NotI* enzyme (New England Biolabs, Cat. #R0189S) for ONNV in 0.05-ml reactions, according to the manufacturer's instructions. *In vitro* transcription was performed by using a SP6 polymerase Megascript kit (Ambion, AM1334) for SINV and a T7 polymerase Megascript kit for ONNV (Ambion, AM1330) in 0.02-ml reactions according to the manufacturer's instructions. Cap analog m7G(5')ppp5'G (Ambion, #AM8048-8052) was used in the transcription reaction, and RNA was purified using a Total RNA kit (Omega, R6834-02; from step 7). Vero or C636 cells were transfected with purified RNA using Transmessenger Transfection Reagent (Qiagen, #301525) according to the manufacturer's instructions (ONNV and SINV), or directly infected with virus particles (MAYV). Cell supernatant was harvested after 24-72 h of incubation and stored in 1 mL aliquots at -70°C.

Alphavirus infections

Seven (SINV and ONNV) or eight (MAYV) days after *Wolbachia* injections, adult mosquitoes were fed on infectious human blood using a glass membrane feeder jacketed with 37°C water. SINV and ONNV were quantified using plaque assays, while MAYV was quantified using focus-forming assays (see below for specific methods). Mosquitoes were sugar-starved overnight prior to blood feeding. Infectious blood meals were prepared by thawing frozen virus stocks to 37°C and adding it to the blood directly prior to feeding. Final blood meal virus titers were: ONNV – 10⁶ pfu/mL; SINV – 10⁵ pfu/mL; MAYV – 10⁷ ffu/mL.

Mosquitoes were allowed to feed for one hour then anesthetized briefly on ice and examined for feeding status, and partially or non-blood fed females discarded. Fully engorged females were randomly divided into two groups and maintained in standard conditions as described above. Infected animals were analyzed at 7 and 14 days post-blood feeding. More

specifically, mosquitoes were anesthetized with trimethylamine and legs from each individual were removed and placed separately into 2-ml microcentrifuge tubes containing 1 ml of mosquito diluent (20% heat-inactivated fetal bovine serum [FBS] in Dulbecco's phosphate-buffered saline, 50 $\mu\text{g ml}^{-1}$ penicillin streptomycin, and 2.5 $\mu\text{g ml}^{-1}$ fungizone). Saliva was collected from mosquito bodies by placing the proboscis of each mosquito into a capillary tube containing 1:1 of 50% sucrose:FBS [40]. After 30 minutes, the capillary tube contents were expelled in individual microcentrifuge tubes containing 0.1 ml of mosquito diluent on ice, while bodies were placed in individual microcentrifuge tubes containing 1 ml of mosquito diluent. A single zinc-plated, steel, 4.5 mm bead (Daisy) was placed into the microcentrifuge tubes containing mosquito bodies and legs. SINV and ONNV samples were homogenized in a mixer mill (Retsch) for 30 seconds at 24 cycles per second, then centrifuged for 1 minute at 10,000 rpm. MAYV samples were homogenized at 30 Hz for 2 min in a TissueLyser II (Qiagen) and centrifuged for 30 sec at 11,000 rpm. All samples were stored at -70°C until use.

Plaque assays

Mosquito samples were tested for SINV or ONNV infectious particles by plaque assay on Vero cells according to previously published protocols [74]. Briefly, 100 μL of each undiluted sample was inoculated onto Vero cell culture monolayers. After inoculated plates were incubated in a cell culture incubator at 37°C and 5% CO_2 for 1 hr, an agar overlay was added (1:1 1x Dulbecco's modified eagle medium, 10% FBS, 1x penicillin streptomycin, 1x fungizone:1.2% agarose). Plates were incubated at 37°C for 2 days and then a second overlay (first overlay plus 1.5% final concentration of neutral red) was added. Twenty-four hours after application of the second overlay, samples were scored as positive or negative, and plaques counted. If plaques were too numerous to count, the assays were repeated with 10-fold serial dilutions of the sample. The infection rate was defined as the proportion of mosquitoes with virus-positive bodies. The dissemination rate was defined as the proportion

of infected mosquitoes with virus-positive legs. The transmission rate was calculated as the proportion of animals with disseminated infections that also had virus-positive saliva, while transmission efficiency was the proportion of total mosquitoes with virus-positive saliva (Figure 1).

Focus forming unit (FFU) assays

Infectious MAYV particles were detected and quantified via FFU assays in Vero cells as previously described [68]. Cells (1×10^4 /well) were grown in 96-well plates at 37°C with 5% CO₂ in complete media (Dulbecco's modified-essential media [DMEM] with 100 units/mL penicillin/streptomycin and 10% FBS). After one day of incubation, cells were briefly washed with DMEM (without FBS) and incubated for 1 h at 37°C with 30 uL of the serially diluted (10^1 to 10^{-4}) mosquito lysate or saliva. After 1 h, the sample was removed, and cells were briefly washed with DMEM to remove any unadhered viral particles. Wells were next filled with 100 uL of overlay medium (1% methylcellulose in complete medium), and plates were incubated. After 24 h (body and leg samples) or 48 h (saliva), cells were fixed with 4% paraformaldehyde (Sigma). Fixed cells were blocked and permeabilized for 30 min in blocking solution (3% bovine serum albumin and 0.05% Tween-20 in PBS) then washed with cold PBS. Viral antigens were next labeled with an anti-alphavirus antibody (CHK-48, BEI Resources) diluted 1:500 in blocking solution. Cells were washed with cold PBS four times, then incubated with Alexa-488 tagged secondary antibody (goat anti-mouse IgG, Invitrogen) at a dilution of 1:500. Fluorescent foci were then counted by eye (in a well with a dilution that produced <100 total foci) using an Olympus BX41 microscope with a UPlan FI 4x objective and FITC filter.

Quantitative real-time PCR of *Wolbachia* density

We extracted DNA from a 250- μ l aliquot of each mosquito body homogenate with the EZNA Tissue DNA kit (Omega, cD3396-02), and DNA was used as a template for qPCR with the

PerfeCta SYBR FastMix kit (Quanta Biosciences) on a Rotor-Gene Q (Qiagen) or a 7500 PCR system (Applied Biosystems). The qPCRs were performed in 10- μ l reactions, and we used the following standardized program for amplification: 95°C for 5 min; 40 cycles of 95°C for 10 sec, 60°C for 15 sec, and 72°C for 10 sec. DNA was amplified with primers specific to each *Wolbachia* strain (*wAlbB*: Alb-GF; GGT-TTT-GCT-TAT-CAA-GCA-AAA-G and Alb-GR; GCG-CTG-TAA-AGA-ACG-TTG-ATC [75]; *wMel*: WD_0550F; CAG-GAG-TTG-CTG-TGG-GTA-TAT-TAG-C and WD_0550R; TGC-AGG-TAA-TGC-AGT-AGC-GTA-AA [76]) and was normalized to host gene S7 (*AeS7F*; GGG-ACA-AAT-CGG-CCA-GGC-TAT-C and *AeS7R*; TCG-TGG-ACG-CTT-CTG-CTT-GTT-G [77]) by using qGene [39, 78].

Statistical analyses

The infection, dissemination, and transmission frequencies for each *Wolbachia* strain and virus combination were compared with controls using pairwise 2x2 Fisher's exact tests. Nonparametric Mann–Whitney U tests were used to compare viral titers when comparing two groups, and the Kruskal–Wallis test with Dunn's correction for multiple comparisons was used to compare experiments with more than two groups. *Wolbachia* titers were analyzed using ANOVA. Statistical tests were performed in GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA). Binomial confidence intervals were calculated using the `binconf()` function in the R package `Hmisc`.

6. Results

***Ae. aegypti* vector competence for alphaviruses SINV and ONNV**

Prior to conducting experiments with *Wolbachia*, we first asked whether *Wolbachia*-free *Ae. aegypti* could be infected with ONNV and SINV. We found *Ae. aegypti* was susceptible to infection (17-20% across two replicates, n=60 total animals) and dissemination (45%, 5 of 11 infected animals) with ONNV, but not transmission (0%). They were susceptible to infection (100% of 60 animals), dissemination (97-100%, at days 7 and 14, respectively), and

transmission (23-38%, at days 7 and 14, respectively) with SINV. We did not test MAYV as our previous work found *Ae. aegypti* to be a competent vector of MAYV; At 7 days post infection with BeAr 505411 strain of MAYV, the infection, dissemination and transmission rates were 86.2%, 60% and 6.7% respectively [68], and other work also found *Ae. aegypti* to be susceptible to infection with MAYV [49].

***Wolbachia* and SINV co-infections**

We asked whether somatic *Wolbachia* infections can influence alphavirus infections in *Ae. aegypti*. Infection rates with SINV were moderate across all treatment groups at both time points (42-69%, Figure 2A). Both *wAlbB*- and *wMel*-injected mosquitoes showed significant enhancement of SINV infection rates compared to control mosquitoes at day 7 (Figure 2A, $P=0.007$ and $P=0.002$, respectively) but not at day 14 ($P>0.05$ for both). Additionally, there was a trend (though not statistically significant) toward *wAlbB*- and *wMel*-induced enhancement of dissemination, especially at day 7 (Figure 2B). Neither *Wolbachia* strain affected SINV transmission (Figure 2C-D). Additionally, *wAlbB* mosquitoes had significantly greater body titers than control mosquitoes at day 7 (Figure 3A, $P=0.0035$). There were no other significant differences in the body or saliva titers between *Wolbachia* and control mosquitoes (Figure 3).

***Wolbachia* and ONNV co-infection**

Infection rates with ONNV were low (0-17%) in all treatment groups (Figure 4A). Neither *Wolbachia* strain had a significant effect on ONNV infection, dissemination, or transmission rates (Figure 4, $P>0.05$ for all comparisons), nor any effects on viral titer (Figure 5, $P>0.05$ for all).

***Wolbachia* and MAYV co-infection**

The effects of *Wolbachia* on MAYV infections were strikingly strain-specific. Control and *wAlbB*-injected mosquitoes were both infected at high rates (85% and 80% infection rates at day 7, respectively, 88% and 74% at day 14) and did not differ statistically at either time point (Figure 6A, $P > 0.05$ for both comparisons). In contrast, *wMel* injected mosquitoes were infected with MAYV only rarely (20% and 28% infection rate at days 7 and 14, Figure 6A, $P < 0.0001$ for both times *versus* controls). MAYV infections were less likely to disseminate in both groups of *Wolbachia* injected mosquitoes (Figure 6B, $P = 0.0028$ and $P = 0.006$ for *wAlbB*, and $P = 0.0008$ and $P = 0.052$ for *wMel*, at 7 and 14 days; note that *wMel* comparisons are affected by small sample sizes due to low infection rate). Transmission was also reduced in most *Wolbachia* injected animals at 14 but not 7 days post injection (Figure 6C-D). Both *Wolbachia* strains reduced infection intensity: *wMel* had a strong suppressive effect (titers were 33-38% of control titers at 7 and 14 days; Figure 7A, $P < 0.0001$ at both time points) while the effects of *wAlbB* were modest (77-75% of control titers; Figure 7A, $P = 0.0394$ and $P = 0.0133$ at 7 and 14 days post-infection, respectively). *wMel* also suppressed viral titer in legs—a proxy for dissemination—at both time points (Figure 7B, $P < 0.0001$ for both comparisons), and in saliva at 14 days post infection (Figure 7C, $P = 0.0040$). In contrast, *wAlbB* had fewer effects on viral titer, but suppressed leg titer at 14 days (Figure 7B, $P = 0.0074$).

7. Discussion

While some mosquito-borne illnesses have declined in recent years (e.g., malaria [79]), *Ae. aegypti*—the primary vector of dengue, yellow fever, chikungunya, and zika viruses—stands out as an increasing threat to global human health [80]. The incidence of dengue, a virus spread primarily by *Ae. aegypti*, has grown 30-fold over the past 50 years and 390 million people may be infected each year [81-82]. *Ae. aegypti* also sparked a new epidemic (Zika virus) by spreading this previously neglected pathogen to new areas of the world [83]. One of the most promising new tools for curbing mosquito-borne disease—and dengue virus in

particular—is *Wolbachia*, a bacterium that can block mosquitoes from transmitting pathogens [15]. However, much remains unknown about the bacterium, including its mechanism(s) of action [13, 37, 84-85]) and how it influences the many diverse viruses *Ae. aegypti* can carry (but see [86-89]). Filling these gaps in our understanding will better inform control programs and help us anticipate situations where *Wolbachia* could potentially exacerbate mosquito-borne transmission of some pathogens even while it suppresses others.

Here we report variable effects of *Wolbachia* on different alphaviruses in *Ae. aegypti*. We found that two divergent *Wolbachia* strains enhanced SINV infection rates seven days post infection, though this effect disappeared by day 14. One possibility is that *Wolbachia* decreases the extrinsic incubation period of this virus, though other mechanisms are possible. In contrast, we did not find significant effects of *Wolbachia* on ONNV infections, and we found *Wolbachia* reduced vector competence for MAYV. This effect varied from strong pathogen blocking (*wMel*) to smaller effects on dissemination and transmission (*wAlbB*), depending on the *Wolbachia* strain used. Our findings agree with earlier work that reported strong suppression of MAYV by a stable *wMel* infection in *Ae. aegypti* [49]. In sum, across three different alphaviruses we found three different effects of *Wolbachia*: enhancement, no effect, and strain-dependent pathogen blocking. These disparities highlight that the effects of *Wolbachia* on viruses are extremely variable. With our limited current knowledge, we cannot predict how *Wolbachia* may alter the composition and transmission of *Ae. aegypti*'s large and growing virome [90-91], which includes numerous human pathogens.

We report that *Wolbachia*-mediated effects can be strain-specific. Most notably, the pathogen blocking effect on MAYV [49] depended strongly on the *Wolbachia* strain used: *wMel* robustly suppressed MAYV infections at both time points while *wAlbB* did not affect infection rate. Our findings comport with previous reports that *Wolbachia* can have strain-

specific effects on both pathogen susceptibility phenotypes and immune priming [89, 92-93]. For example, one study in *Ae. aegypti* found the *Wolbachia* strain *wMel* did not have any effects on yellow fever virus, but the *wMelPop* strain significantly reduced yellow fever virus in mosquito bodies and heads [89]. We do not yet know the mechanism underlying these strain-specific differences. However, we do know that *Wolbachia* strains show substantial genetic variation [6], which may provide one path for uncovering the molecular basis of these differential effects.

Neither *Wolbachia* strain had a significant effect on ONNV vector competence or viral body titers. Though we did see a trend toward possible enhancement of these viral measures, low infection rates affected statistical power. Overall, *Ae. aegypti* in general was a poor vector for ONNV, consistent with reports that *Anopheles* mosquitoes are the main vectors of ONNV [65-66]. However, some studies have suggested that *Ae. aegypti* vector competence for ONNV may be strain-specific, and that this species can be a good vector in some circumstances [66]. Future studies should continue to test *Ae. aegypti* competence for this neglected alphavirus as well as whether *Wolbachia* may enhance ONNV transmission.

Though we do not yet understand why *Wolbachia* has variable effects on diverse viruses including WNV, Rift Valley Fever virus, SINV, ONNV, and MAYV, previous work hints at potential mechanisms. First, viruses from different families may interact within the host and with *Wolbachia* strains in diverse ways, e.g., via distinct immune responses [94]. Another possibility is the nature of the *Wolbachia* infections: this work used transient *Wolbachia* infections rather than stable, maternally inherited *Wolbachia* infections. However, several pieces of evidence suggest a broad similarity between transient and stable infections. Both transient and stable infections can show widespread tissue tropism [21, 39, 95], and transient and stable *Wolbachia* infections also have similar pathogen-blocking effects on WNV and DENV in *Ae. aegypti* [96]. Transient *Wolbachia* infections also strongly blocked

MAYV infections in the present study, replicating previous findings using stable infections [49]. Thus, the variation we describe may instead arise from previously unexplored biotic or abiotic factors that influence interactions between *Wolbachia* and these pathogens.

There are several limitations to our study. Although transient and somatic *Wolbachia* infections have similar effects on both DENV [96] and MAYV [49] in *Ae. aegypti*, it remains to be seen whether (and how) stable *Wolbachia* infections in *Ae. aegypti* affect the alphaviruses studied here. Future work could explore whether *Wolbachia* infection techniques differentially impact pathogens. We also only examined a single viral genotype for each virus and did not compare multiple mosquito genotypes.

Our results illustrate the importance of further research into the effects of *Wolbachia* on arboviruses and the underlying mechanisms of those effects. *Wolbachia* has been deployed widely in the field, yet numerous studies have shown there is substantial variation in the bacterium's effects on vector competence. Factors such as environmental conditions, the *Wolbachia* strain used, the targeted pathogen, the mosquito species, and even rearing conditions appear to influence outcomes (e.g., [97-100]), yet the exact mechanism(s) driving this variation remain unclear. A better understanding of when and how *Wolbachia* influences viral infections in mosquitoes is needed in order to predict the long-range and knock-on effects this bacterium may have on the spread of human pathogens.

8. Author statements

8.1 Authors and contributors

B.L.D., S.P., M.B. and J.L.R. conceptualized this research and designed the experiments.

B.L.D., S.P., M.B., and H.C.M. collected and analyzed the data. B.L.D., H.C.M., and J.L.R.

wrote the paper.

8.2 Conflicts of interest

The author(s) declare that there are no conflicts of interest.

8.3 Funding information

This study was supported by NIH grants R01AI116636 and R01AI150251, USDA Hatch funds (Accession #1010032; Project #PEN04608), a grant with the Pennsylvania Department of Health using Tobacco Settlement Funds, and funds from the Dorothy Foehr Huck and J. Lloyd Huck endowment to JLR.

8.4 Ethical approval

All methods were carried out in accordance with The Pennsylvania State University institutional guidelines and regulations.

8.5 Acknowledgements

We thank Dr. George Dimopoulos of Johns Hopkins University for kindly sharing the Rockefeller strain of *Ae. aegypti* mosquitoes. We thank Dr. Brian Foy of Colorado State University for kindly sharing SINV (p5'dsMRE16ic) and ONNV (p5'dsONNVic/foy) plasmids.

Abbreviations

DENV, Dengue virus

FBS, fetal bovine serum

FFU, focus forming units

MAYV, Mayaro virus

ONNV, O'nyong-nyong virus

PBS, phosphate buffered saline

PFU, plaque forming units

SINV, Sindbis virus

WNV, West Nile virus

9. References

1. World Health Organization. A global brief on vector-borne diseases. (2014). Geneva. Retrieved from www.who.int
2. Kilpatrick, A. M., & Randolph, S. E. (2012). Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. *Lancet*, 380(9857), 1946–1955. [https://doi.org/10.1016/S0140-6736\(12\)61151-9](https://doi.org/10.1016/S0140-6736(12)61151-9).
3. Tabachnick, W. J. (2010). Challenges in predicting climate and environmental effects on vector-borne disease epistystems in a changing world. *The Journal of Experimental Biology*, 213(6), 946–954. <https://doi.org/10.1242/jeb.037564>
4. Weaver, S. C., & Reisen, W. K. (2010). Present and future arboviral threats. *Antiviral Research*, 85(2), 328–345. <https://doi.org/10.1016/j.antiviral.2009.10.008>
5. Campbell LP, Luther C, Moo-Llanes D, Ramsey JM, Danis-Lozano R, Peterson AT. Climate change influences on global distributions of dengue and chikungunya virus vectors. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2015 ; 370(1665):20140135. <https://doi.org/10.1098/rstb.2014.0135>
6. Sicard, M., Bonneau, M., Weill M. 2019. Wolbachia prevalence, diversity, and ability to induce cytoplasmic incompatibility in mosquitoes. *Curr Opin Insect Sci* 34:12-20. <https://doi.org/10.1016/j.cois.2019.02.005>

7. Bourtzis, K., Dobson, S. L., Xi, Z., Rasgon, J. L., Calvitti, M., Moreira, L. A., ... Gilles, J. R. L. (2014). Harnessing mosquito-Wolbachia symbiosis for vector and disease control. *Acta Tropica*, 132S, S150–S163.
<https://doi.org/10.1016/j.actatropica.2013.11.004>
8. Caragata EP, Dutra HL, Sucupira PH, Ferreira AG, Moreira LA. Wolbachia as translational science: controlling mosquito-borne pathogens. *Trends in Parasitology*. 2021 Dec 1;37(12):1050-67. <https://doi.org/10.1016/j.pt.2021.06.007>
9. Hoffmann, A. A., Montgomery, B. L., Popovici, J., Iturbe-Ormaetxe, I., Johnson, P. H., Muzzi, F., ... O'Neill, S. L. (2011). Successful establishment of Wolbachia in *Aedes* populations to suppress dengue transmission. *Nature*, 476(7361), 454–457.
<https://doi.org/10.1038/nature10356>
10. Werren, J. H. (1997). Biology of Wolbachia. *Annual Review of Entomology*, 42(124), 587–609. <https://doi.org/10.1146/annurev.ento.42.1.587>
11. Zug R, Hammerstein P. Still a host of hosts for Wolbachia: analysis of recent data suggests that 40% of terrestrial arthropod species are infected. *PloS one*. 2012 Jun 7;7(6):e38544. <https://doi.org/10.1371/journal.pone.0038544>
12. Dutra, H. L. C., Rocha, M. N., Dias, F. B. S., Mansur, S. B., Caragata, E. P., & Moreira, L. A. (2016). Wolbachia blocks currently circulating Zika virus isolates in Brazilian *Aedes aegypti* mosquitoes. *Cell Host and Microbe*, 19(6), 771–774.
<https://doi.org/10.1016/j.chom.2016.04.021>
13. Moreira, L. A., Iturbe-Ormaetxe, I., Jeffery, J. A., Lu, G., Pyke, A. T., Hedges, L. M., ... O'Neill, S. L. (2009). A Wolbachia symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and Plasmodium. *Cell*, 139(7), 1268–1278.
<https://doi.org/10.1016/j.cell.2009.11.042>

14. Tan, C. H., Wong, P. J., Li, M. I., Yang, H., Ng, C., & Neill, S. L. O. (2017). wMel limits zika and chikungunya virus infection in a Singapore Wolbachia - introgressed Ae. aegypti strain, wMel-Sg. *PLoS Neglected Tropical Diseases*, 11(5), e0005496. <https://doi.org/10.1371/journal.pntd.0005496>
15. Walker, T., Johnson, P. H., Moreira, L. A., Iturbe-Ormaetxe, I., Frentiu, F. D., McMeniman, C. J., ... Hoffmann, A. A. (2011). The wMel Wolbachia strain blocks dengue and invades caged *Aedes aegypti* populations. *Nature*, 476(7361), 450–453. <https://doi.org/10.1038/nature10355>
16. Garcia GD, Sylvestre G, Aguiar R, da Costa GB, Martins AJ, Lima JB, Petersen MT, Lourenço-de-Oliveira R, Shadbolt MF, Rašić G, Hoffmann AA. Matching the genetics of released and local *Aedes aegypti* populations is critical to assure Wolbachia invasion. *PLoS neglected tropical diseases*. 2019 Jan 8;13(1):e0007023. <https://doi.org/10.1371/journal.pntd.0007023>
17. Nazni WA, Hoffmann AA, NoorAfizah A, Cheong YL, Mancini MV, Golding N, Kamarul GM, Arif MA, Thohir H, NurSyamimi H, ZatilAqmar MZ. Establishment of Wolbachia strain wAlbB in Malaysian populations of *Aedes aegypti* for dengue control. *Current biology*. 2019 Dec 16;29(24):4241-8. <https://doi.org/10.1016/j.cub.2019.11.007>
18. Crawford JE, Clarke DW, Criswell V, Desnoyer M, Cornel D, Deegan B, Gong K, Hopkins KC, Howell P, Hyde JS, Livni J. Efficient production of male Wolbachia-infected *Aedes aegypti* mosquitoes enables large-scale suppression of wild populations. *Nature Biotechnology*. 2020, 38(4):482-92. <https://doi.org/10.1038/s41587-020-0471-x>
19. Tantowijoyo W, Andari B, Arguni E, Budiwati N, Nurhayati I, Fitriana I, Ernesia I, Daniwijaya EW, Supriyati E, YUSDIANA DH, Victorius M. Stable establishment of

- wMel Wolbachia in *Aedes aegypti* populations in Yogyakarta, Indonesia. *PLoS neglected tropical diseases*. 2020, 14(4):e0008157.
<https://doi.org/10.1371/journal.pntd.0008157>
20. The World Mosquito Program's project sites around the world. (n.d.). Retrieved September 26, 2017, from <http://www.eliminatedengue.com/project>
21. Frentiu, F. D., Zakir, T., Walker, T., Popovici, J., Pyke, A. T., van den Hurk, A., ... O'Neill, S. L. (2014). Limited dengue virus replication in field-collected *Aedes aegypti* mosquitoes infected with Wolbachia. *PLoS Neglected Tropical Diseases*, 8(2), e2688. <https://doi.org/10.1371/journal.pntd.0002688>
22. Hoffmann AA, Iturbe-Ormaetxe I, Callahan AG, Phillips BL, Billington K, Axford JK, Montgomery B, Turley AP, O'Neill SL. Stability of the wMel Wolbachia infection following invasion into *Aedes aegypti* populations. *PLoS neglected tropical diseases*. 2014, 8(9):e3115. <https://doi.org/10.1371/journal.pntd.0003115>
23. Turley, A. P., Schmidt, T. L., Barton, N. H., Ras, G., Montgomery, L., Iturbe-ormaeetxe, I., ... Turelli, M. (2017). Local introduction and heterogeneous spatial spread of dengue-suppressing Wolbachia through an urban population of *Aedes aegypti*. *PLoS Biology*, 15(5), e2001894.
<https://doi.org/10.1371/journal.pbio.2001894>
24. Ryan PA, Turley AP, Wilson G, Hurst TP, Retzki K, Brown-Kenyon J, Hodgson L, Kenny N, Cook H, Montgomery BL, Paton CJ. Establishment of wMel Wolbachia in *Aedes aegypti* mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland, Australia. *Gates open research*. 2019;3. <https://doi.org/10.12688/gatesopenres.13061.2>
25. Ross PA, Robinson KL, Yang Q, Callahan AG, Schmidt TL, Axford JK, Coquilleau MP, Staunton KM, Townsend M, Ritchie SA, Lau MJ. A decade of stability for wMel

- Wolbachia in natural *Aedes aegypti* populations. *PLoS pathogens*. 2022 Feb 23;18(2):e1010256. <https://doi.org/10.1371/journal.ppat.1010256>
26. Hussain, M., Lu, G., Torres, S., Edmonds, J. H., Kay, B. H., Khromykh, A. A., & Asgari, S. (2013). Effect of Wolbachia on replication of West Nile virus in a mosquito cell line and adult mosquitoes. *Journal of Virology*, 87(2), 851–858. <https://doi.org/10.1128/JVI.01837-12>
27. Nguyen, T. H., Nguyen, H. Le, Nguyen, T. Y., Vu, S. N., Tran, N. D., Le, T. N., ... Hoffmann, A. A. (2015). Field evaluation of the establishment potential of *wmelpop* Wolbachia in Australia and Vietnam for dengue control. *Parasites & Vectors*, 8, 563. <https://doi.org/10.1186/s13071-015-1174-x>
28. Osborne, S. E., Leong, Y. S., O'Neill, S. L., & Johnson, K. N. (2009). Variation in antiviral protection mediated by different Wolbachia strains in *Drosophila simulans*. *PLoS Pathogens*, 5(11), e1000656. <https://doi.org/10.1371/journal.ppat.1000656>
29. Teixeira, L., Ferreira, A., & Ashburner, M. (2008). The bacterial symbiont Wolbachia induces resistance to RNA viral infections in *Drosophila melanogaster*. *PLoS Biology*, 6(12), e1000002. <https://doi.org/10.1371/journal.pbio.1000002>
30. Lau MJ, Ross PA, Hoffmann AA. Infertility and fecundity loss of Wolbachia-infected *Aedes aegypti* hatched from quiescent eggs is expected to alter invasion dynamics. *PLoS neglected tropical diseases*. 2021 Feb 16;15(2):e0009179. <https://doi.org/10.1371/journal.pntd.0009179>
31. Ross, P., Wiwatanaratnabutr, I., Axford, J. K., White, V. L., Endersby-Harshman, N. M., & Hoffmann, A. A. (2016). Wolbachia infections in *Aedes aegypti* differ markedly in their response to cyclical heat stress. *PLoS Pathogens*, 13(1), e1006006. <https://doi.org/10.1101/073106>

32. Hancock, P. A., White, V. L., Callahan, A. G., Godfray, C. H. J., Hoffmann, A. A., & Ritchie, S. A. (2016). Density-dependent population dynamics in *Aedes aegypti* slow the spread of wMel Wolbachia. *Journal of Applied Ecology*, 53, 785–793.
<https://doi.org/10.1111/1365-2664.12620>
33. Lu, P., Bian, G., Pan, X., & Xi, Z. (2012). Wolbachia induces density-dependent inhibition to dengue virus in mosquito cells. *PLoS Neglected Tropical Diseases*, 6(7), e1754. <https://doi.org/10.1371/journal.pntd.0001754>
34. Martinez, J., Longdon, B., Bauer, S., Chan, Y.-S., Miller, W. J., Bourtzis, K., ... Jiggins, F. M. (2014). Symbionts commonly provide broad spectrum resistance to viruses in insects: A comparative analysis of Wolbachia strains. *PLoS Pathogens*, 10(9), e1004369. <https://doi.org/10.1371/journal.ppat.1004369>
35. Murdock, C. C., Blanford, S., Hughes, G. L., Rasgon, J. L., & Thomas, M. B. (2014). Temperature alters Plasmodium blocking by Wolbachia. *Scientific Reports*, 4, 3932. <https://doi.org/10.1038/srep03932>
36. Baton LA, Pacidônio EC, Goncalves DD, Moreira LA. w Flu: characterization and evaluation of a native Wolbachia from the mosquito *Aedes fluviatilis* as a potential vector control agent. *PloS one*. 2013; 8(3):e59619.
<https://doi.org/10.1371/journal.pone.0059619>
37. Hughes, G. L., Vega-Rodriguez, J., Xue, P., & Rasgon, J. L. (2012). Wolbachia strain wAlbB enhances infection by the rodent malaria parasite *Plasmodium berghei* in *Anopheles gambiae* mosquitoes. *Applied and Environmental Microbiology*, 78(5), 1491–1495. <https://doi.org/10.1128/AEM.06751-11>
38. Zélé, F., Nicot, A., Berthomieu, A., Weill, M., Duron, O., Rivero, A., & B, P. R. S. (2014). Wolbachia increases susceptibility to Plasmodium infection in a natural

- system. Proceedings of the Royal Society, 281(1779):20132837.
<https://doi.org/10.1098/rspb.2013.2837>
39. Dodson, B. L., Hughes, G. L., Paul, O., Matarachero, A. C., Kramer, L. D., Rasgon, J. L. (2014). Wolbachia infection enhances West Nile virus (WNV) infection in the mosquito *Culex tarsalis*. PLoS Neglected Tropical Diseases, 8(7), e2965.
<https://doi.org/10.1371/journal.pntd.0002965>
40. Dodson BL, Andrews ES, Turell MJ, Rasgon JL. Wolbachia effects on Rift Valley fever virus infection in *Culex tarsalis* mosquitoes. PLoS neglected tropical diseases. 2017, 30;11(10):e0006050. <https://doi.org/10.1371/journal.pntd.0006050>
41. Gloria-Soria, A., Chiodo, T.G. and Powell, J.R., 2018. Lack of evidence for natural Wolbachia infections in *Aedes aegypti* (Diptera: Culicidae). Journal of Medical Entomology, 55(5), 1354-1356. <https://doi.org/10.1093/jme/tjy084>
42. Ross PA, Callahan AG, Yang Q, Jasper M, Arif MA, Afizah AN, Nazni WA, Hoffmann AA. An elusive endosymbiont: Does Wolbachia occur naturally in *Aedes aegypti*? Ecology and Evolution. 2020, 10(3):1581-91. <https://doi.org/10.1002/ece3.6012>
43. Dutra, H. L. C., Caragata, E. P., & Moreira, L. A. (2017). Prospects & Overviews The re-emerging arboviral threat: Hidden enemies. Bioessays, 2, 1–10.
<https://doi.org/10.1002/bies.201600175>
44. Halstead S. B. (2015). Reappearance of chikungunya, formerly called dengue, in the Americas. Emerging infectious diseases, 21(4), 557–561.
<https://doi.org/10.3201/eid2104.141723>
45. Powers, A. N. N. M., Brault, A. C., Shirako, Y., Strauss, E. G., Kang, W., Strauss, J. H., & Weaver, S. C. (2001). Evolutionary relationships and systematics of the Alphaviruses. Journal of Virology, 75(21), 10118–10131.
<https://doi.org/10.1128/JVI.75.21.10118>

46. Lounibos LP, Kramer LD. Invasiveness of *Aedes aegypti* and *Aedes albopictus* and vectorial capacity for chikungunya virus. *The Journal of Infectious Diseases*. 2016, 15;214(suppl_5):S453–8. <https://doi.org/10.1093/infdis/jiw285>
47. ECDC. “Facts about Sindbis Fever.” (2017). Retrieved from <https://ecdc.europa.eu/en/sindbis-fever/facts>
48. Lwande OW, Obanda V, Bucht G, Mosomtai G, Otieno V, Ahlm C, Evander M. Global Emergence of Alphaviruses known to cause arthralgia in humans. *Infection Ecology & Epidemiology*. 2015;5. DOI:10.3402/iee.v5.29853
49. Pereira, T.N., Rocha, M.N., Sucupira, P.H.F. *et al.* *Wolbachia* significantly impacts the vector competence of *Aedes aegypti* for Mayaro virus. *Sci Rep* 8, 6889 (2018). <https://doi.org/10.1038/s41598-018-25236-8>
50. Taylor, R. M., Hurlbut, H. S., Work, T. H., Kingston, J., & Frothingham, T. (1955). Sindbis virus: a newly recognized arthropod-transmitted virus. *American Journal of Tropical Medicine and Hygiene*, 4(5), 844–862. <https://doi.org/10.4269/ajtmh.1955.4.844>
51. Hubálek, Z. (2008). Mosquito-borne viruses in Europe. *Parasitological Research*, 103, S29–S43. <https://doi.org/10.1007/s00436-008-1064-7>
52. Kurkela, S., Manni, T., Vaheri, A., & Vapalahti, O. (2004). Causative agent of Pogosta disease isolated from blood and skin lesions. *Emerging Infectious Diseases*, 10(5), 889–894. <https://doi.org/10.3201/eid1005.030689>
53. Liu, H., Gao, X., & Liang, G. (2011). Newly recognized mosquito-associated viruses in mainland China in the last two decades. *Virology Journal*, 8(68). <https://doi.org/10.1186/1743-422X-8-68>
54. Lvov, D. K., Neronov, V. M., Gromashevsky, V. L., Skvortsova, T. M., Berezina, L. K., Sidorova, G. A., ... Fomina, K. B. (1976). “Karshi” virus, a new flavivirus

- (Togaviridae) isolated from *Ornithodoros papillipes* (Birula, 1895) ticks in Uzbek S.S.R. *Archives of Virology*, 50(1–2), 29–36. <https://doi.org/10.1007/BF01317998>
55. Lvov, D. K., Vladimirtseva, E. A., Butenko, A. M., Karabatsos, N., Trent, D. W., & Calisher, A. N. C. H. (1988). Identity of Karelian fever and Ockelbo viruses determined by serum dilution-plaque reduction neutralization tests and oligonucleotide mapping. *The American Society of Tropical Medicine and Hygiene*, 39(6), 607–610. <https://doi.org/10.4269/ajtmh.1988.39.607>
56. McIntosh, B. M., Jupp, P. G., Dos Santos, I., & Meenehan, G. M. (1976). Epidemics of West Nile and Sindbis viruses in South Africa with *Culex univittatus* Theobald as vector. *South African Journal of Science*, 72(10), 295–300.
57. Skogh, M., & Espmark, A. (1982). Ockelbo disease: epidemic arthritis-exanthema syndrome in Sweden caused by Sindbis-virus like agent. *The Lancet*, 3(1), 795–796. [https://doi.org/10.1016/s0140-6736\(82\)91834-7](https://doi.org/10.1016/s0140-6736(82)91834-7)
58. Jost, H., Bialonski, A., Storch, V., Gu, S., Becker, N., & Schmidt-Chanasit, J. (2010). Isolation and phylogenetic analysis of Sindbis viruses from mosquitoes in Germany. *Journal of Clinical Microbiology*, 48(5), 1900–1903. <https://doi.org/10.1128/JCM.00037-10>
59. Kramer, L. D., Chin, P., Cane, R. P., Kauffman, E. B., & Mackereth, G. (2011). Vector competence of New Zealand mosquitoes for selected arboviruses. *American Journal of Tropical Medicine and Hygiene*, 85(1), 182–189. <https://doi.org/10.4269/ajtmh.2011.11-0078>
60. Haddow, A. J., Davies, C. W., & Walker, A. J. (1960). O'nyong-nyong fever: an epidemic virus disease in East Africa 1. Introduction. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 54(6), 517–522. [https://doi.org/10.1016/0035-9203\(60\)90025-0](https://doi.org/10.1016/0035-9203(60)90025-0)

61. Labeaud, A. D., Banda, T., Brichard, J., Muchiri, E. M., Mungai, L., Mutuku, F. M., ... King, C. H. (2015). High rates of o'nyong nyong and chikungunya virus transmission in coastal Kenya. *PLoS Neglected Tropical Diseases*, 9(2), e0003436. <https://doi.org/10.1371/journal.pntd.0003436>
62. Lanciotti, R. S., Ludwig, M. L., Rwaguma, E. B., Lutwama, J. J., Kram, T. M., Karabatsos, N., ... Miller, B. R. (1998). Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence: genetic characterization of the virus. *Virology*, 252(1), 258–268. <https://doi.org/10.1006/viro.1998.9437>
63. Powers, A. M., Brault, A. C., Tesh, R. B., & Weaver, S. C. (2000). Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. *Journal of General Virology*, 81, 471–479. <https://doi.org/10.1099/0022-1317-81-2-471>
64. Tappe, D., Kapaun, A., & Emmerich, P. (2014). O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. *Emerging Infectious Diseases*, 20(10), 9–10. <https://doi.org/10.3201/eid2010.140823>
65. Corbet, P. S., Williams, M. C., & Gillett, J. D. (1961). O'nyong-nyong fever: an epidemic virus disease in East Africa. IV. Vector studies at epidemic sites. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 55(5), 463–480. [https://doi.org/10.1016/0035-9203\(61\)90095-5](https://doi.org/10.1016/0035-9203(61)90095-5)
66. Vanlandingham, D. L., Hong, C., Klingler, K., Tsetsarkin, K., McElroy, K. L., Powers, A. M., ... Higgs, S. (2005). Differential infectivities of o'nyong-nyong and chikungunya virus isolates in *Anopheles gambiae* and *Aedes aegypti* mosquitoes. *The American Journal of Tropical Medicine and Hygiene*, 72(5), 616–621.

67. Mackay IM, Arden KE. Mayaro virus: a forest virus primed for a trip to the city?.
Microbes and infection. 2016 Dec 1;18(12):724-34.
<https://doi.org/10.1016/j.micinf.2016.10.007>
68. Brustolin M, Pujhari S, Henderson CA, Rasgon JL. Anopheles mosquitoes may drive invasion and transmission of Mayaro virus across geographically diverse regions.
PLoS neglected tropical diseases. 2018, 12(11):e0006895.
<https://doi.org/10.1371/journal.pntd.0006895>
69. Long, K.C., Ziegler, S.A., Thangamani, S., Hausser, N.L., Kochel, T.J., Higgs, S. and Tesh, R.B. (2011). Experimental transmission of Mayaro virus by *Aedes aegypti*. The American Journal of Tropical Medicine and Hygiene, 85(4):750.
<https://doi.org/10.4269/ajtmh.2011.11-0359>
70. Wiggins, K., Eastmond, B., & Alto, B. W. (2018). Transmission potential of Mayaro virus in Florida *Aedes aegypti* and *Aedes albopictus* mosquitoes. Medical and veterinary entomology, 32(4), 436–442. <https://doi.org/10.1111/mve.12322>
71. Rasgon, J. L., Gamston, C. E., & Ren, X. (2006). Survival of *Wolbachia pipientis* in cell-free medium. Applied and Environmental Microbiology, 72(11), 6934–6937.
<https://doi.org/10.1128/AEM.01673-06>
72. Brault, A., Foy, B., Myles, K., Kelly, C., Higgs, S., Weaver, S., ... Powers, A. (2004). Infection patterns of o'nyong nyong virus in the malaria- transmitting mosquito, *Anopheles gambiae*. Insect Molecular Biology, 13(6), 625–635.
<https://doi.org/10.1111/j.0962-1075.2004.00521.x>
73. Foy, B. D., Myles, K. M., Pierro, D. J., Sanchez-Vargas, I., Uhlírová, M., Jindra, M., ... Olson, K. E. (2004). Development of a new Sindbis virus transducing system and its characterization in three Culicine mosquitoes and two Lepidopteran species.

- Insect Molecular Biology, 13(1), 89–100. <https://doi.org/10.1111/j.1365-2583.2004.00464.x>
74. Blow, J. A., Dohm, D. J., Negley, D. L., & Mores, C. N. (2004). Virus inactivation by nucleic acid extraction reagents. *Journal of Virological Methods*, 119, 195–198. <https://doi.org/10.1016/j.jviromet.2004.03.015>
75. Hughes, G.L., Koga, R., Xue, P., Fukatsu, T. and Rasgon, J.L. (2011). Wolbachia infections are virulent and inhibit the human malaria parasite *Plasmodium falciparum* in *Anopheles gambiae*. *PLoS pathogens*, 7(5), p.e1002043. <https://doi.org/10.1371/journal.ppat.1002043>
76. McMeniman, C. J., Lane, A. M., Fong, A. W. C., Voronin, D. A., Iturbe-Ormaetxe, I., Yamada, R., ... O'Neill, S. L. (2008). Host adaptation of a Wolbachia strain after long-term serial passage in mosquito cell lines. *Applied and Environmental Microbiology*, 74(22), 6963–6969. <https://doi.org/10.1128/AEM.01038-08>
77. Xi, Z., Ramirez, J. L., & Dimopoulos, G. (2008). The *Aedes aegypti* Toll pathway controls dengue virus infection. *PLoS Pathogens*, 4(7), e1000098. <https://doi.org/10.1371/journal.ppat.1000098>
78. Simon, P. (2003). Q-Gene: processing quantitative real-time RT-PCR data. *Bioinformatics*, 19(11), 1439–1440. <https://doi.org/10.1093/bioinformatics/btg157>
79. World Health Organization. (2021) World malaria report. Retrieved from www.who.int
80. Kraemer MU, Reiner RC, Brady OJ, Messina JP, Gilbert M, Pigott DM, Yi D, Johnson K, Earl L, Marczak LB, Shirude S. Past and future spread of the arbovirus vectors *Aedes aegypti* and *Aedes albopictus*. *Nature Microbiology*. 2019 May;4(5):854-63. <https://doi.org/10.1038/s41564-019-0376-y>
81. World Health Organization. (2019). Retrieved from: <https://www.who.int/news-room/questions-and-answers/item/dengue-and-severe-dengue>

82. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF. The global distribution and burden of dengue. *Nature*. 2013, 496(7446):504-7. <https://doi.org/10.1038/nature12060>
83. Hennessey, M., Fischer, M., & Staples, J. E. (2016). Zika virus spreads to new areas — region of the Americas, May 2015 – January 2016. *Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report*, 65(3), 1–4. <https://doi.org/10.15585/mmwr.mm6503e1>
84. Newton, I. L. G., Clark, M. E., Kent, B. N., Bordenstein, S. R., Qu, J., Richards, S., ... Werren, J. H. (2016). Comparative genomics of two closely related *Wolbachia* with different reproductive effects on hosts. *Genome Biology and Evolution*, 8(5), 1526–1542. <https://doi.org/10.1093/gbe/evw096>
85. Terradas G, McGraw EA. *Wolbachia*-mediated virus blocking in the mosquito vector *Aedes aegypti*. *Current Opinion in Insect Science*. 2017 22:37-44. <https://doi.org/10.1016/j.cois.2017.05.005>
86. Aliota MT, Peinado SA, Velez ID, Osorio JE. The wMel strain of *Wolbachia* reduces transmission of Zika virus by *Aedes aegypti*. *Scientific Reports*. 2016; 6(1):1-7. <https://doi.org/10.1038/srep28792>
87. Aliota MT, Walker EC, Uribe Yepes A, Dario Velez I, Christensen BM, Osorio JE. The w Mel strain of *Wolbachia* reduces transmission of chikungunya virus in *Aedes aegypti*. *PLoS Neglected Tropical Diseases*. 2016; 10(4):e0004677. <https://doi.org/10.1371/journal.pntd.0004677>
88. Bian G, Xu Y, Lu P, Xie Y, Xi Z. The endosymbiotic bacterium *Wolbachia* induces resistance to dengue virus in *Aedes aegypti*. *PLoS pathogens*. 2010; 6(4):e1000833. <https://doi.org/10.1371/journal.ppat.1000833>

89. van den Hurk, A. F., Hall-Mendelin, S., Pyke, A. T., Frentiu, F. D., McElroy, K., Day, A., ... O'Neill, S. L. (2012). Impact of Wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector *Aedes aegypti*. *PLoS Neglected Tropical Diseases*, 6(11), e1892. <https://doi.org/10.1371/journal.pntd.0001892>
90. Parry R, James ME, Asgari S. Uncovering the worldwide diversity and evolution of the virome of the mosquitoes *Aedes aegypti* and *Aedes albopictus*. *Microorganisms*. 2021 Aug;9(8):1653. <https://doi.org/10.3390/microorganisms9081653>
91. Atoni E, Zhao L, Karungu S, Obanda V, Agwanda B, Xia H, Yuan Z. The discovery and global distribution of novel mosquito-associated viruses in the last decade (2007-2017). *Reviews in Medical Virology*. 2019 Nov;29(6):e2079. <https://doi.org/10.1002/rmv.2079>
92. Osborne, S. E., Iturbe-Ormaetxe, I., Brownlie, J. C., O'Neill, S. L., & Johnson, K. N. (2012). Antiviral protection and the importance of Wolbachia density and tissue tropism in *Drosophila simulans*. *Applied and Environmental Microbiology*, 78(19), 6922–6929. <https://doi.org/10.1128/AEM.01727-12>
93. Ye, Y. H., Woolfit, M., Rancès, E., O'Neill, S. L., & McGraw, E. A. (2013). Wolbachia-associated bacterial protection in the mosquito *Aedes aegypti*. *PLoS Neglected Tropical Diseases*, 7(8), e2362. <https://doi.org/10.1371/journal.pntd.0002362>
94. Jupatanakul, N., Sim, S., Angleró-Rodríguez, Y. I., Souza-Neto, J., Das, S., Poti, K. E., ... Dimopoulos, G. (2017). Engineered *Aedes aegypti* JAK/STAT pathway-mediated immunity to dengue virus. *PLOS Neglected Tropical Diseases*, 11(1), e0005187. <https://doi.org/10.1371/journal.pntd.0005187>
95. Dobson, S. L., Bourtzis, K., Braig, H. R., Jones, B. F., Zhou, W., Rousset, F., & O'Neill, S. L. (1999). Wolbachia infections are distributed throughout insect somatic

and germ line tissues. *Insect Biochemistry and Molecular Biology*, 29(2), 153–160.

[https://doi.org/10.1016/S0965-1748\(98\)00119-2](https://doi.org/10.1016/S0965-1748(98)00119-2)

96. Joubert, D. A., & O'Neill, S. L. (2017). Comparison of stable and transient *Wolbachia* infection models in *Aedes aegypti* to block dengue and West Nile viruses. *PLoS Neglected Tropical Diseases*, 11, e0005275.

<https://doi.org/10.1371/journal.pntd.0005275>

97. Dutton, T. J., & Sinkins, S. P. (2004). Strain-specific quantification of *Wolbachia* density in *Aedes albopictus* and effects of larval rearing conditions. *Insect Molecular Biology*, 13(3), 317–322. <https://doi.org/10.1111/j.0962-1075.2004.00490.x>

98. Mouton, L., Henri, H., Charif, D., Bouletreau, M., & Vavre, F. (2007). Interaction between host genotype and environmental conditions affects bacterial density in *Wolbachia* symbiosis. *Biology Letters*, 3(2), 210–213.

<https://doi.org/10.1098/rsbl.2006.0590>

99. Ross, P. A., Endersby, N. M., & Hoffmann, A. A. (2016). Costs of three *Wolbachia* infections on the survival of *Aedes aegypti* larvae under starvation conditions. *PLoS Neglected Tropical Diseases*, 10(1), 1–22.

<https://doi.org/10.1371/journal.pntd.0004320>

100. Wiwatanaratanabutr, I., & Kittayapong, P. (2009). Effects of crowding and temperature on *Wolbachia* infection density among life cycle stages of *Aedes albopictus*. *Journal of Invertebrate Pathology*, 102(3), 220–224.

<https://doi.org/10.1016/j.jip.2009.08.009>

10. Figures




Figure 1. Schematic of study design and timeline. Adult *Aedes aegypti* females were somatically infected with *Wolbachia* (wAlbB or wMel) or a control solution via injection 2-5 days post-eclosion. Seven or eight days later, injected animals consumed a blood meal spiked with infectious alphavirus (ONNV, SINV, or MAYV). At 7 and 14 days post-blood feeding, viral titers were measured in three tissues. *Wolbachia* infection density was additionally quantified in SINV- and ONNV-exposed animals.




Figure 2. Effects of *Wolbachia* infection on SINV vector competence in *Aedes aegypti*. **(A)** SINV infection rates 7 and 14 days post-blood feeding. **(B)** SINV dissemination rates in infected mosquitoes (from **A**) at 7 and 14 days post-blood feeding. **(C)** SINV transmission rates in mosquitoes with disseminated infections (from **B**), at 7 and 14 days post-blood feeding. **(D)** SINV transmission efficiency at 7 and 14 days post-blood feeding. Dots indicate binomial point estimates and error bars show binomial 95% confidence intervals. Groups were compared using pairwise Fisher's exact tests. ** $P < 0.01$.




Figure 3. SINV titers in *Wolbachia*-infected and control animals. **(A)** Body titers, and **(B)** saliva titers, at 7 and 14 days post-infected blood meal. Horizontal lines mark group medians. Groups were compared by Kruskal-Wallis tests with Dunn's correction. ** $P < 0.01$.




Figure 4. Effects of *Wolbachia* infection on ONNV vector competence in *Aedes aegypti*. **(A)** ONNV infection rates 7 and 14 days post-blood feeding. **(B)** ONNV dissemination rates in infected mosquitoes (from **A**) at 7 and 14 days post-blood feeding, **(C)** ONNV transmission rates in mosquitoes with disseminated infections (from **B**), at 7 and 14 days post-blood feeding, **(D)** ONNV transmission efficiency at 7 and 14 days post-blood feeding. Dots indicate binomial point estimates and error bars show binomial 95% confidence intervals. Groups were compared using pairwise Fisher's exact tests. No significant differences were found.




Figure 5. ONNV titers in *Wolbachia*-infected and control animals. **(A)** Body titers, and **(B)** saliva titers, at 7 and 14 days post-infected blood meal. Groups were compared by or Kruskal-Wallis tests with Dunn's correction. There were no significant differences between groups.




Figure 6. Effects of *Wolbachia* infection on MAYV vector competence in *Aedes aegypti*. **(A)** MAYV infection rates 7 and 14 days post-blood feeding. **(B)** MAYV dissemination rates in infected mosquitoes (from **A**) at 7 and 14 days post-blood feeding, **(C)** MAYV transmission rates in mosquitoes with disseminated infections (from **B**), at 7 and 14 days post-blood feeding, **(D)** SINV transmission efficiency at 7 and 14 days post-blood feeding. Dots indicate binomial point estimates and error bars show binomial 95% confidence intervals. Groups were compared using pairwise Fisher's exact tests. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.




Figure 7. MAYV titers in *Wolbachia*-infected and control animals. (A) Body titers, (B) leg titers, and (C) saliva titers at 7 and 14 days post-infected blood meal. Horizontal lines mark group medians. Groups were compared by Kruskal-Wallis tests with Dunn's correction. * $P < 0.05$, ** $P < 0.01$, **** $P < 0.0001$.

Supplementary material:




Figure S1. *Wolbachia* (wAlbB and wMel) titers (*Wolbachia* genomes/host genomes) in somatically-infected *Aedes aegypti* 7 and 14 days post-injection. Groups are not statistically different (ANOVA, $P = 0.39$).